← Eichor
Condition: Cutaneous Peripheral T Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cutaneous Peripheral T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04045470A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Phase 1 · 3 location(s) · Memorial Sloan Kettering Cancer Center · NCT05296304Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06914037Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07047885Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT05956041Photopheresis in Early-stage Mycosis Fungoides
Phase 2 · 1 location(s) · Columbia University · NCT05680558Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT04930653Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Phase N/A · 1 location(s) · Northwestern University · NCT03932279A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/Phase 2 · 37 location(s) · Dren Bio · NCT05475925Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
Phase N/A · 1 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06382844MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
NA · 1 location(s) · Centre Hospitalier Universitaire de Besancon · NCT05333367A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05996185Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell
Phase 1/Phase 2 · 4 location(s) · City of Hope Medical Center · NCT03011814Amping up With PemJAK
Phase 2 · 1 location(s) · Seda S. Tolu · NCT07283822Tissue Repository: CTCL Collection Protocol
Phase N/A · 1 location(s) · Columbia University · NCT02840747A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTC
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06698822JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 · 2 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06716658Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB
Phase 2 · 13 location(s) · European Organisation for Research and Treatment of Cancer - · NCT04128072Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05313243A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 · 15 location(s) · Prescient Therapeutics, Ltd. · NCT06854653A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Phase 2 · 1 location(s) · Jonathan Brammer · NCT07356245A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Phase N/A · 3 location(s) · Peking University First Hospital · NCT06436677
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.